PURPOSE: To develop a Risk Score (RS) to predict distant recurrence among premenopausal women with node-negative endocrine-responsive early breast cancer. METHODS: The Cox model was used to develop the RS using clinical and histopathological features from 378 women participating in the IBCSG Trial VIII who received endocrine therapy alone or following chemotherapy. The performance of the resulting model was validated on a cohort of 1005 patients from a single institution who received endocrine therapy alone. RESULTS: In a multivariable analysis, the risk of distant recurrence was associated with tumor size, ER, Ki-67 and peritumoral vascular invasion. In the validation cohort, patients with high RS were at greater risk of distant recurrence compared to patients with low RS (HR, 17.41; 95% CI, 5.72-52.95). CONCLUSION: In premenopausal women with node-negative endocrine-responsive early breast cancer, the RS identifies patients at higher risk of distant recurrence.
PURPOSE: To develop a Risk Score (RS) to predict distant recurrence among premenopausal women with node-negative endocrine-responsive early breast cancer. METHODS: The Cox model was used to develop the RS using clinical and histopathological features from 378 women participating in the IBCSG Trial VIII who received endocrine therapy alone or following chemotherapy. The performance of the resulting model was validated on a cohort of 1005 patients from a single institution who received endocrine therapy alone. RESULTS: In a multivariable analysis, the risk of distant recurrence was associated with tumor size, ER, Ki-67 and peritumoral vascular invasion. In the validation cohort, patients with high RS were at greater risk of distant recurrence compared to patients with low RS (HR, 17.41; 95% CI, 5.72-52.95). CONCLUSION: In premenopausal women with node-negative endocrine-responsive early breast cancer, the RS identifies patients at higher risk of distant recurrence.
Authors: P Birner; G Oberhuber; J Stani; C Reithofer; H Samonigg; H Hausmaninger; E Kubista; W Kwasny; D Kandioler-Eckersberger; M Gnant; R Jakesz Journal: Clin Cancer Res Date: 2001-06 Impact factor: 12.531
Authors: Ivo A Olivotto; Chris D Bajdik; Peter M Ravdin; Caroline H Speers; Andrew J Coldman; Brian D Norris; Greg J Davis; Stephen K Chia; Karen A Gelmon Journal: J Clin Oncol Date: 2005-04-20 Impact factor: 44.544
Authors: Monica Castiglione-Gertsch; Anne O'Neill; Karen N Price; Aron Goldhirsch; Alan S Coates; Marco Colleoni; M Laura Nasi; Marco Bonetti; Richard D Gelber Journal: J Natl Cancer Inst Date: 2003-12-17 Impact factor: 13.506
Authors: Marc J van de Vijver; Yudong D He; Laura J van't Veer; Hongyue Dai; Augustinus A M Hart; Dorien W Voskuil; George J Schreiber; Johannes L Peterse; Chris Roberts; Matthew J Marton; Mark Parrish; Douwe Atsma; Anke Witteveen; Annuska Glas; Leonie Delahaye; Tony van der Velde; Harry Bartelink; Sjoerd Rodenhuis; Emiel T Rutgers; Stephen H Friend; René Bernards Journal: N Engl J Med Date: 2002-12-19 Impact factor: 91.245
Authors: Xifeng Wu; Yuanqing Ye; Carlos H Barcenas; Wong-Ho Chow; Qing H Meng; Mariana Chavez-MacGregor; Michelle A T Hildebrandt; Hua Zhao; Xiangjun Gu; Yang Deng; Elizabeth Wagar; Francisco J Esteva; Debu Tripathy; Gabriel N Hortobagyi Journal: J Natl Cancer Inst Date: 2017-07-01 Impact factor: 13.506